Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Cefepime microbiologic profile and update.

Kessler RE.

Pediatr Infect Dis J. 2001 Mar;20(3):331-6. Review.

PMID:
11303846
2.

Identification and characterization of cell wall-cell division gene clusters in pathogenic gram-positive cocci.

Pucci MJ, Thanassi JA, Discotto LF, Kessler RE, Dougherty TJ.

J Bacteriol. 1997 Sep;179(17):5632-5.

3.

Perspectives on chemotherapeutic approaches to antibiotic-resistant bacteria.

Kessler RE.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S146-7.

PMID:
8994795
4.

Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli.

Dougherty TJ, Kennedy K, Kessler RE, Pucci MJ.

J Bacteriol. 1996 Nov;178(21):6110-5.

5.

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.

Sanders WE Jr, Tenney JH, Kessler RE.

Clin Infect Dis. 1996 Sep;23(3):454-61.

PMID:
8879764
6.
7.

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1996 May;40(5):1289-93.

8.

Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Fung-Tomc JC, Huczko E, Banville J, Ménard M, Kolek B, Gradelski E, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):394-9.

9.

Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Fung-Tomc JC, Gradelski E, Kolek B, Minassian B, Pucci M, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):386-93.

10.

In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.

Kessler RE, Fung-Tomc J, Kolek B, Minassian B, Huczko E, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):380-5.

11.

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE.

Antimicrob Agents Chemother. 1995 Feb;39(2):295-300.

12.

Susceptibility of United States clinical trial isolates to cefprozil and cefaclor.

Kessler RE, Fung-Tomc JC.

Diagn Microbiol Infect Dis. 1994 Feb;18(2):129-32.

PMID:
8062532
13.

Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.

Gradelski E, Fung-Tomc J, Huczko E, Kessler RE.

J Antimicrob Chemother. 1993 Nov;32 Suppl B:75-80.

PMID:
8150769
14.

beta-Lactamase parameters of heterogeneously and homogeneously methicillin-resistant Staphylococcus aureus.

Gradelski E, Huczko E, Kessler RE, Bonner DP, Fung-Tomc J.

J Antimicrob Chemother. 1993 Mar;31(3):441-2. No abstract available.

PMID:
8486580
15.

Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones.

Di Cesare P, Bouzard D, Essiz M, Jacquet JP, Ledoussal B, Kiechel JR, Remuzon P, Kessler RE, Fung-Tomc J, Desiderio J.

J Med Chem. 1992 Oct 30;35(22):4205-13.

PMID:
1433222
16.

Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.

Bouzard D, Di Cesare P, Essiz M, Jacquet JP, Ledoussal B, Remuzon P, Kessler RE, Fung-Tomc J.

J Med Chem. 1992 Feb 7;35(3):518-25.

PMID:
1738144
17.

In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.

Fung-Tomc J, Huczko E, Kolek B, Thater C, Kessler RE.

Antimicrob Agents Chemother. 1991 Dec;35(12):2652-4.

18.

Emergence of homogeneously methicillin-resistant Staphylococcus aureus.

Fung-Tomc J, Huczko E, Gradelski E, Denbleyker K, Bonner DP, Kessler RE.

J Clin Microbiol. 1991 Dec;29(12):2880-3.

19.
20.

Inability of cephalothin testing to predict cefprozil susceptibility.

Fung-Tomc J, Stickle T, Doyle C, Huczko E, Kessler RE.

J Clin Microbiol. 1991 Nov;29(11):2643-7.

22.

Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats.

Tsai YH, Bies M, Leitner F, Kessler RE.

Antimicrob Agents Chemother. 1990 May;34(5):733-8.

23.

Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.

Bouzard D, Di Cesare P, Essiz M, Jacquet JP, Kiechel JR, Remuzon P, Weber A, Oki T, Masuyoshi M, Kessler RE, et al.

J Med Chem. 1990 May;33(5):1344-52.

PMID:
2329555
24.

In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.

Fung-Tomc J, Desiderio JV, Tsai YH, Warr G, Kessler RE.

Antimicrob Agents Chemother. 1989 Jun;33(6):906-14.

25.

In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.

Tomatsu K, Masuyoshi S, Hirano M, Kawaguchi H, Oki T, Fung-Tomc J, Desiderio JV, Kessler RE.

Antimicrob Agents Chemother. 1989 Apr;33(4):489-97.

26.

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE.

Antimicrob Agents Chemother. 1989 Apr;33(4):498-502.

27.

Comparison of the inhibitory and bactericidal activity of aztreonam and amikacin against gram negative aerobic bacilli.

Fung-Tomc JC, Lincourt W, Thater C, Kessler RE.

Ann Clin Lab Sci. 1988 Nov-Dec;18(6):463-7.

PMID:
3239949
28.

Glucan-binding factor in saliva.

Cowan MM, Parrish K, Kessler RE, Pyle C Jr, Taylor KG, Ciardi JE, Doyle RJ.

Infect Immun. 1988 Nov;56(11):2912-7.

29.

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Fung-Tomc J, Huczko E, Pearce M, Kessler RE.

Antimicrob Agents Chemother. 1988 Sep;32(9):1443-5.

31.

BMY 28100, a new oral cephalosporin.

Leitner F, Pursiano TA, Buck RE, Tsai YH, Chisholm DR, Misiek M, Desiderio JV, Kessler RE.

Antimicrob Agents Chemother. 1987 Feb;31(2):238-43.

33.

Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Phelps DJ, Carlton DD, Farrell CA, Kessler RE.

Antimicrob Agents Chemother. 1986 May;29(5):845-8.

35.

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Kessler RE, Bies M, Buck RE, Chisholm DR, Pursiano TA, Tsai YH, Misiek M, Price KE, Leitner F.

Antimicrob Agents Chemother. 1985 Feb;27(2):207-16.

36.
38.
39.

Increased carbohydrate substitution of lipoteichoic acid during inhibition of protein synthesis.

Kessler RE, Wicken AJ, Shockman GD.

J Bacteriol. 1983 Jul;155(1):138-44.

40.

Plasmid content of Streptococcus faecalis strain 39-5 and identification of a pheromone (cPD1)-induced surface antigen.

Yagi Y, Kessler RE, Shaw JH, Lopatin DE, An F, Clewell DB.

J Gen Microbiol. 1983 Apr;129(4):1207-15.

PMID:
6411857
42.
43.

Effect of portal venous blood flow diversion on portal pressure.

Zimmon DS, Kessler RE.

J Clin Invest. 1980 Jun;65(6):1388-97.

44.

Growth characteristics of group A streptococci in a new chemically defined medium.

van de Rijn I, Kessler RE.

Infect Immun. 1980 Feb;27(2):444-8.

45.
46.

Quantitative immunoelectrophoretic analysis of Streptococcus pyogenes membrane.

Kessler RE, van de Rijn I.

Infect Immun. 1979 Dec;26(3):892-902.

47.
49.
50.

Limulus lysate activity of lipoteichoic acids.

Fine DH, Kessler RE, Tabak LA, Shockman GD.

J Dent Res. 1977 Dec;56(12):1500. No abstract available.

PMID:
98539

Supplemental Content

Loading ...
Support Center